Uusi-Kerttula H - Search Results

1

Ad5_NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL. Uusi-Kerttula H, et al. Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24. Clin Cancer Res. 2018. PMID: 29798908

2

Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5_NULL-A20.

Davies JA, Marlow G, Uusi-Kerttula HK, Seaton G, Piggott L, Badder LM, Clarkson RWE, Chester JD, Parker AL. Davies JA, et al. Among authors: uusi kerttula hk. Viruses. 2021 May 8;13(5):864. doi: 10.3390/v13050864. Viruses. 2021. PMID: 34066836 Free PMC article.

3

Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.

Hulin-Curtis SL, Uusi-Kerttula H, Jones R, Hanna L, Chester JD, Parker AL. Hulin-Curtis SL, et al. Among authors: uusi kerttula h. Cancer Gene Ther. 2016 Jul;23(7):229-34. doi: 10.1038/cgt.2016.22. Epub 2016 May 27. Cancer Gene Ther. 2016. PMID: 27229159 Free PMC article.

4

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Uusi-Kerttula H, et al. Viruses. 2015 Nov 24;7(11):6009-42. doi: 10.3390/v7112923. Viruses. 2015. PMID: 26610547 Free PMC article. Review.

5

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL. Uusi-Kerttula H, et al. Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545. Oncotarget. 2016. PMID: 27056886 Free PMC article.

6

Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.

Bates EA, Davies JA, Váňová J, Nestić D, Meniel VS, Koushyar S, Cunliffe TG, Mundy RM, Moses E, Uusi-Kerttula HK, Baker AT, Cole DK, Majhen D, Rizkallah PJ, Phesse T, Chester JD, Parker AL. Bates EA, et al. Among authors: uusi kerttula hk. Mol Ther Oncolytics. 2022 Mar 16;25:43-56. doi: 10.1016/j.omto.2022.03.007. eCollection 2022 Jun 16. Mol Ther Oncolytics. 2022. PMID: 35399606 Free PMC article.

7

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL. Uusi-Kerttula H, et al. Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015. Hum Gene Ther. 2015. PMID: 25919378 Free PMC article.

8

Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions.

Baker AT, Greenshields-Watson A, Coughlan L, Davies JA, Uusi-Kerttula H, Cole DK, Rizkallah PJ, Parker AL. Baker AT, et al. Among authors: uusi kerttula h. Nat Commun. 2019 Feb 14;10(1):741. doi: 10.1038/s41467-019-08599-y. Nat Commun. 2019. PMID: 30765704 Free PMC article.

9

Precision virotherapies: Coming soon.

Uusi-Kerttula H, Parker AL. Uusi-Kerttula H, et al. Oncotarget. 2018 Nov 2;9(86):35605-35606. doi: 10.18632/oncotarget.26280. eCollection 2018 Nov 2. Oncotarget. 2018. PMID: 30479689 Free PMC article. No abstract available.

10

Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.

Coughlan L, Uusi-Kerttula H, Ma J, Degg BP, Parker AL, Baker AH. Coughlan L, et al. Hum Gene Ther. 2014 Apr;25(4):385-94. doi: 10.1089/hum.2014.016. Epub 2014 Apr 11. Hum Gene Ther. 2014. PMID: 24617540

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page